Why the study?
Elevated NCC and phosphorylated NCC are potential markers of primary aldosteronism, but whether these effects are driven by hypokalemia remains unclear.
Does acute oral potassium chloride supplementation reduce the abundance and phosphorylation of the sodium-chloride cotransporter in patients with primary aldosteronism?
Does acute oral potassium chloride supplementation reduce the abundance and phosphorylation of the sodium-chloride cotransporter in patients with primary aldosteronism?
Acute potassium supplementation in primary aldosteronism suppresses sodium-chloride cotransporter abundance and phosphorylation, suggesting that hypokalemia overrides the stimulatory effect of aldosterone on NCC.
Answers are grounded in this paper and cite their sources.
Low K+ may dominate NCC regulation in primary aldosteronism despite high aldosterone; leaves open effects of supplementation on outcomes.
Key Points Potassium chloride intake induced a reduction in sodium-chloride cotransporter (NCC) and phosphorylated NCC in urinary extracellular vesicles from patients with primary aldosteronism during a significantly raised level of endogenous aldosterone. Low plasma potassium (secondary to aldosterone excess) may dominate in terms of NCC regulation in the setting of primary aldosteronism. Background Elevated abundance of sodium-chloride cotransporter (NCC) and phosphorylated NCC (pNCC) are potential markers of primary aldosteronism (PA), but these effects may be driven by hypokalemia. Methods We measured plasma potassium in patients with PA. If potassium was <4.0 mmol/L, patients were given sufficient oral potassium chloride (KCl) over 24 hours to achieve as close to 4.0 mmol/L as possible. Clinical chemistries were assessed, and urinary extracellular vesicles (uEVs) were examined to investigate effects on NCC. Results Among 21 patients with PA who received a median total dose of 6.0 g (2.4–16.8 g) of KCl, increases were observed in plasma potassium (from 3.4 to 4.0 mmol/L; P <0.001), aldosterone (from 305 to 558 pmol/L; P= 0.01), and renin (from 1.2 to 2.5 mIU/L; P <0.001), whereas decreases were detected in uEV levels of NCC (median fold change (post/basal) [FC]=0.71 [0.09–1.99]; P= 0.02), pT60-NCC (FC=0.84 [0.06–1.66]; P= 0.05), and pT55/60-NCC (FC=0.67 [0.08–2.42]; P= 0.02). By contrast, in 10 patients with PA who did not receive KCl, there were no apparent changes in plasma potassium, NCC abundance, and phosphorylation status, but increases were observed in plasma aldosterone (from 178 to 418 pmol/L; P= 0.006) and renin (from 2.0 to 3.0 mU/L; P= 0.009). Plasma potassium correlated inversely with uEV levels of NCC ( R 2 =0.11; P= 0.01), pT60-NCC ( R 2 =0.11; P =0.01), and pT55/60-NCC ( R 2 =0.11; P =0.01). Conclusions Acute oral KCl loading replenished plasma potassium in patients with PA and suppressed NCC abundance and phosphorylation, despite a significant rise in plasma aldosterone. This supports the view that potassium supplementation in humans with PA overrides the aldosterone stimulatory effect on NCC. The increased plasma aldosterone in patients with PA without KCl supplementation may be due to aldosterone response to posture challenge.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: